EMV Capital Limited
EMV Capital Ltd (EMVC) is a London-based pan-European award-winning investor focused on B2B companies in the industrial high-tech, clean energy, resource efficiency, circular economy, smart cities and transportation sectors. EMVC invests in, and provides advisory services related to, investments that involve a range of technologies including robotics and AI, machine vision, materials science, IoT, advanced engineering and power electronics. EMVC’s model is to develop a customized investment strategy for each company, combining its network of investors from Family Offices, Wealth Managers, Institutional VC investors and Corporate VC funds. While not an impact investor, EMVC understand the importance and value of environmental sustainability and ethical investment principles, reflecting this within its investment thesis and. EMVC recognizes the benefits of corporate engagement for early-stage technology companies, with EMVC’s team having led and structured investments alongside some of the world’s leading corporations, including ABB, Philips Lighting, Evonik Industries, Mitsubishi and Flex.
Founded by Dr. Ilian Iliev, EMVC has a unique multidisciplinary team with expertise in investment, deep industry, corporate finance and M&A. EMV Capital Limited is an appointed representative of Sapphire Capital Limited, which is authorised and regulated by the Financial Conduct Authority. EMV Capital is also exclusive advisor to the EMVC Evergreen EIS Fund.
Example portfolio companies
Developing a unique solution to steer the radio signal towards the receiver—improving range and performance of the antenna, whilst reducing the power required to operate the network, thereby avoiding the need for expensive cooling systems. Sofant’s patented smart antenna technology enables the steering of radio signals in future wireless systems in the 5G and SatCom space.
A US-based oncology diagnostic company, developing a novel liquid biopsy automated instrument (VTX-1) and microfluidic cartridge for the isolation of circulating tumour cells from whole blood without the need for any pre-treatment. Vortex Biosciences’ main mission is to become the innovation leader in CTC capture technology delivering diagnostic tests that improve therapeutic decisions and save lives. The key potential is to revolutionize cancer diagnosis leading to better therapeutic outcomes. Its technology integrates cancer biology, microfluidic engineering, clinical research and the identification of cancer therapies and drug targets.
A remote monitoring healthcare analytics and management company for primary care patients with chronic diseases based in San Francisco. Wanda’s ambition is to significantly control and reduce hospitalisation rates through a Remote Monitoring System (RMS) that collects data from patients’ home to clinicians highlighting the high risks and allowing the action to prevent them. This life personalised medicine combined with secure computing and revolutionary data-mining and analytics improves the quality of life for people with chronic conditions, initially focused on congestive heart failure (CHF). Chronic disease in the US is accounted for 80% of the total health care bill representing a US$1.4 trillion expenditure. This could be significantly decreased through a severe chronic disease management and appropriate clinical measures.